PubMed Health⌕ Search

PubMed · 12296616

Post-stroke depression.

Abstract

Stroke is considered mainly as a physical disability, and stroke-related depression is under-recognised. Cognitive, language and functional impairment complicates the recognition of post-stroke depression. The pathophysiology of post-stroke depression is poorly understood, but several risk factors have been identified. Depression following stroke can impede recovery and rehabilitation and is associated with higher mortality Randomised trials show that antidepressants, especially selective serotonin uptake inhibitors, are effective in the treatment of this condition. Despite the evidence available, a large number of patients remain undertreated. Early identification and treatment can reduce the functional impairment and mortality related to post-stroke depression.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Gupta, K Pansari, H Shetty. 2002. Post-stroke depression.. https://pubmed.ncbi.nlm.nih.gov/12296616/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring.

Therapeutic drug monitoring necessitates efficient, fast and reliable analytical methods validated by external quality control. We therefore devised an isocratic reversed-phase HPLC method with ultraviolet detection and optimised this to quantify mirtazapine, reboxetine, moclobemide, venlafaxine, O-desmethylvenlafaxine, paroxetine, fluvoxamine, fluoxetine, norfluoxetine, sertraline, citalopram, amitriptyline, nortriptyline, imipramine, desipramine, doxepin, nordoxepin, clomipramine, norclomipramine, trimipramine, mianserine, maprotiline, normaprotiline, amisulpride, clozapine, norclozapine, quetiapine, risperidone and 9-OH-risperidone in human serum. After solid-phase extraction of the drugs and metabolites, the chromatographic separation was achieved on a Nucleosil 100-Protect 1 column with acetonitrile-potassium dihydrogenphosphate buffer as mobile phase. The method was validated for therapeutic and toxic serum ranges. A linear relationship (r>0.998) was obtained between the concentration and the detector signal. Recoveries were between 75 and 99% for the drugs and metabolites. The accuracy of the quality control samples, expressed as percent recovery, ranged from 91 to 118%; intra- and inter-assay-relative standard deviations were 0.9-10.2% and 0.9-9.7%, respectively. Additional external quality control is carried out since 3 years. This method is applicable to rapidly and effectively analyze serum or plasma samples for therapeutic drug monitoring of about 30 antidepressants and atypical antipsychotics.

Antidepressive Agents↗